Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2032077 | Advances in Medical Sciences | 2010 | 4 Pages |
Abstract
The evaluation of gene and protein expression profiles is a promising strategy to drive the therapeutical decision-making in non-small cell lung cancer (NSCLC). Among the several candidate genes that have been proposed, many retrospective studies have indicated excision repair cross-complementing 1 (ERCC1), an endonuclease responsible for the repair of DNA damages, as a reliable biomarker of tumor sensitivity to platinum-based agents. Moreover, the recent evidences showing the clinical efficacy of next-generation multitargeted antifolate drugs, in NSCLC, have highlighted the role of the determination of thymidylate synthase (TS) expression levels. Here is presented a brief overview of the literature regarding these two genes that are currently under prospective investigation as predictive markers of treatment efficacy in NSCLC.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry, Genetics and Molecular Biology (General)
Authors
P Ceppi, M Papotti, G Scagliotti,